This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Humana's (HUM) 2024 MA Plans Promise a Wider Set of Benefits
by Zacks Equity Research
Humana (HUM) aims to expand the reach of its Medicare plans across newer U.S. counties in 2024 through integrating multiple lucrative benefits within them.
Alcon (ALC) Loses -6.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Alcon (ALC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Protect Your Portfolio From Volatility With 3 Low-Beta Picks
by Indrajit Bandyopadhyay
At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.
Here's Why Investors Should Retain Acadia Healthcare (ACHC)
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on the solid demand for behavioral healthcare services, the continuous pursuit of expansion initiatives and growing cash reserves.
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Molina (MOH) have performed compared to their sector so far this year.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of its portfolio.
Alcon (ALC) Gains From Innovation & International Expansion
by Zacks Equity Research
Alcon's (ALC) Surgical business continues to gain from diverse portfolio and incremental innovation.
Top Stock Reports for Visa, Chubb & HCA Healthcare
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Chubb Limited (CB) and HCA Healthcare, Inc. (HCA).
Waters (WAT) Walk-Up Solutions Boost Bioprocess Development
by Zacks Equity Research
Waters (WAT) launches new bioprocess walk-up solutions, automating sample prep and analysis from any bioreactor.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong growth in membership, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity
by Zacks Equity Research
Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.
Community Health (CYH), Mindoula to Offer Mental Health Care
by Zacks Equity Research
Community Health (CYH) collaborates with Mindoula to enhance the availability of behavioral health resources to its affiliated provider network, who can now treat patients better.
Are Options Traders Betting on a Big Move in Alcon (ALC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alcon (ALC) stock based on the movements in the options market lately.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
by Zacks Equity Research
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.
3 MedTech Stocks to Bet on Potential Pause of Rate Hike by Fed
by Indrajit Bandyopadhyay
Interest rates impact the healthcare industry and medical device companies in various ways. Here we discuss three companies HCA, ALC and SEM that are likely to gain potential pause in rate hikes.
Centene (CNC) Divests Circle Health Group, Optimizes Portfolio
by Zacks Equity Research
Centene (CNC) announces the sale of Circle Health Group to PureHealth in a bid to dispose of non-core assets and grow its core Managed Care business.
Cigna (CI) Eases Care Delivery With Prior Authorization Removal
by Zacks Equity Research
Cigna's (CI) branch, Cigna Healthcare, lifts the prior authorization requirement on 600-plus medical services, thereby easing administrative burdens and making way for simplified care delivery.
Has Alcon (ALC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
3 Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Time to Buy These Medical Stocks as Earnings Approach
by Shaun Pruitt
Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.
Alcon (ALC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alcon (ALC) might have benefitted from the high win rate of Argos Biometer in the second quarter.
Here's Why You Should Invest in Alcon (ALC) Stock Now
by Zacks Equity Research
Investors are optimistic about Alcon (ALC) owing to its strength in Surgical and Vision Care franchises and upbeat 2023 guidance.
Zacks Industry Outlook Highlights Alcon, Hologic and Penumbra
by Zacks Equity Research
Alcon, Hologic and Penumbra have been highlighted in this Industry Outlook article.